Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/41173 |
Resumo: | Colaboração de dados de Carlos Sarina (Fiocruz Brasília). |
id |
CRUZ_55e1687990f2c1b9ee7594c6ee0eb1ff |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/41173 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Hungria, Emerith MayraBührer-Sékula, SamiraOliveira, Regiane Morillas deAderaldo, Lúcio CartaxoPontes, Maria Araci de AndradeCruz, RossileneGonçalves, Heitor de SáPenna, Maria Lucia FernandesPenna, Gerson OliveiraStefani, Mariane Martins de Araújo2020-05-08T19:10:51Z2020-05-08T19:10:51Z2018HUNGRIA, Emerith M. et al. Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT. Frontiers in Immunology, [Lausanne], v. 9, n. 915, p. 1-15, May 2018.1664-3224https://www.arca.fiocruz.br/handle/icict/4117310.3389/fimmu.2018.00915Colaboração de dados de Carlos Sarina (Fiocruz Brasília).MS/DECIT/CNPqUniversidade Federal de Goiás. Instituto de Patologia Tropical e Saúde Pública. Goiânia, GO, Brasil.Universidade Federal de Goiás. Instituto de Patologia Tropical e Saúde Pública. Goiânia, GO, Brasil.Universidade Federal de Goiás. Instituto de Patologia Tropical e Saúde Pública. Goiânia, GO, Brasil.Centro de Dermatologia Dona Libânia, Fortaleza, CE, Brasil.Centro de Dermatologia Dona Libânia, Fortaleza, CE, Brasil.Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta. Manaus, AM, Brasil.Centro de Dermatologia Dona Libânia, Fortaleza, CE, Brasil.Universidade Federal Fluminense. Departamento de Epidemiologia e Bioestatística. Niterói, RJ, Brasil.Universidade de Brasília. Faculdade de Medicina. Núcleo de Medicina Tropical. Brasília, DF, Brasil / Fundação Oswaldo Cruz. Fiocruz Brasília. Brasília, DF, Brasil.Universidade Federal de Goiás. Instituto de Patologia Tropical e Saúde Pública. Goiânia, GO, Brasil.Leprosy serology reflects the bacillary load of patients and multidrug therapy (MDT) reduces Mycobacterium leprae-specific antibody titers of multibacillary (MB) patients. The Clinical Trial for Uniform Multidrug Therapy Regimen for Leprosy Patients in Brazil (U-MDT/CT-BR) compared outcomes of regular 12 doses MDT/R-MDT and the uniform 6 doses MDT/U-MDT for MB leprosy, both of regimens including rifampicin, clofazimine, and dapsone. This study investigated the impact of R-MDT and U-MDT and the kinetic of antibody responses to M. leprae-specific antigens in MB patients from the U-MDT/CT-BR. We tested 3,400 serum samples from 263 MB patients (R-MDT:121; U-MDT:142) recruited at two Brazilian reference centers (Dona Libânia, Fortaleza, Ceará; Alfredo da Matta Foundation, Manaus, Amazonas). Enzyme-linked immunosorbent assays with three M. leprae antigens [NT-P-BSA: trisaccharide-phenyl of phenollic glycolipid-I antigen (PGL-I); LID-1: Leprosy Infectious Disease Research Institute Diagnostic 1 di-fusion recombinant protein; and ND-O-LID: fusion complex of disaccharide-octyl of PGL-I and LID-1] were performed using around 13 samples per patient. Samples were collected at baseline/M0, during MDT (R-MDT:M1-M12 months, U-MDT:M1-M6 months) and after MDT discontinuation (first, second year). Statistical significance was assessed by the Mann-Whitney U test for comparison between groups (p values < 0.05). Mixed effect multilevel regression analyses were used to investigate intraindividual serological changes overtime. In R-MDT and U-MDT groups, males predominated, median age was 41 and 40.5 years, most patients were borderline lepromatous and lepromatous leprosy (R-MDT:88%, U-MDT: 90%). The bacilloscopic index at diagnosis was similar (medians: 3.6 in the R-MDT and 3.8 in the U-MDT group). In R-MDT and U-MDT groups, a significant decline in anti-PGL-I positivity was observed from M0 to M5 (p = 0.035, p = 0.04, respectively), from M6 to M12 and at the first and second year posttreatment (p < 0.05). Anti-LID-1 antibodies declined from M0 to M6 (p = 0.024), M7 to M12 in the R-MDT; from M0 to M4 (p = 0.003), M5 to M12 in the U-MDT and posttreatment in both groups (p > 0.0001). Anti-ND-O-LID antibodies decreased during and after treatment in both groups, similarly to anti-PGL-I antibodies. Intraindividual serology results in R-MDT and U-MDT patients showed that the difference in serology decay to all three antigens was dependent upon time only. Our serology findings in MB leprosy show that regardless of the duration of the U-MDT and R-MDT, both of them reduce M. leprae-specific antibodies during and after treatment. In leprosy, antibody levels are considered a surrogate marker of the bacillary load; therefore, our serological results suggest that shorter U-MDT is also effective in reducing the patients' bacillary burden similarly to R-MDT.engFrontiers MediaAntibodies, BacterialAntigens, BacterialAntitubercular AgentsClofazimineDapsoneDrug Administration ScheduleEnzyme-Linked Immunosorbent AssayImmunoglobulin MLeprosy, MultibacillaryMycobacterium lepraeRandomized Controlled Trials as TopicRifampinTreatment OutcomeLID-1ND-O-LIDLeprosyMultidrug therapyPhenollic glycolipid-I antigenSerologyMycobacterium lepraeHanseníaseSorologiaAntígenos de BactériasEnsaios Clínicos Controlados Aleatórios como AssuntoResultado do TratamentoEsquema de MedicaçãoMycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDTinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83074https://www.arca.fiocruz.br/bitstream/icict/41173/1/license.txtd3e717dbb24bfc607ede047f44d29a0eMD51ORIGINALve_Emerith_Hungria_etal.pdfve_Emerith_Hungria_etal.pdfArtigoapplication/pdf2228426https://www.arca.fiocruz.br/bitstream/icict/41173/2/ve_Emerith_Hungria_etal.pdf6f48fcb00d676b0e7c8abe65ad0835d7MD52ve_Emerith_Hungria_etal_Suppl.pdfve_Emerith_Hungria_etal_Suppl.pdfSuplementoapplication/pdf690067https://www.arca.fiocruz.br/bitstream/icict/41173/3/ve_Emerith_Hungria_etal_Suppl.pdf5c91d51444abe5add995680271ebb53bMD53TEXTve_Emerith_Hungria_etal.pdf.txtve_Emerith_Hungria_etal.pdf.txtExtracted texttext/plain58563https://www.arca.fiocruz.br/bitstream/icict/41173/4/ve_Emerith_Hungria_etal.pdf.txt79ab1d791b9076dd1818f5959d432111MD54ve_Emerith_Hungria_etal_Suppl.pdf.txtve_Emerith_Hungria_etal_Suppl.pdf.txtExtracted texttext/plain3374https://www.arca.fiocruz.br/bitstream/icict/41173/5/ve_Emerith_Hungria_etal_Suppl.pdf.txt0d9a63f57a606295e96698a93983f134MD55icict/411732020-06-12 10:14:11.446oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352020-06-12T13:14:11Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT |
title |
Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT |
spellingShingle |
Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT Hungria, Emerith Mayra Antibodies, Bacterial Antigens, Bacterial Antitubercular Agents Clofazimine Dapsone Drug Administration Schedule Enzyme-Linked Immunosorbent Assay Immunoglobulin M Leprosy, Multibacillary Mycobacterium leprae Randomized Controlled Trials as Topic Rifampin Treatment Outcome LID-1 ND-O-LID Leprosy Multidrug therapy Phenollic glycolipid-I antigen Serology Mycobacterium leprae Hanseníase Sorologia Antígenos de Bactérias Ensaios Clínicos Controlados Aleatórios como Assunto Resultado do Tratamento Esquema de Medicação |
title_short |
Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT |
title_full |
Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT |
title_fullStr |
Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT |
title_full_unstemmed |
Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT |
title_sort |
Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT |
author |
Hungria, Emerith Mayra |
author_facet |
Hungria, Emerith Mayra Bührer-Sékula, Samira Oliveira, Regiane Morillas de Aderaldo, Lúcio Cartaxo Pontes, Maria Araci de Andrade Cruz, Rossilene Gonçalves, Heitor de Sá Penna, Maria Lucia Fernandes Penna, Gerson Oliveira Stefani, Mariane Martins de Araújo |
author_role |
author |
author2 |
Bührer-Sékula, Samira Oliveira, Regiane Morillas de Aderaldo, Lúcio Cartaxo Pontes, Maria Araci de Andrade Cruz, Rossilene Gonçalves, Heitor de Sá Penna, Maria Lucia Fernandes Penna, Gerson Oliveira Stefani, Mariane Martins de Araújo |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Hungria, Emerith Mayra Bührer-Sékula, Samira Oliveira, Regiane Morillas de Aderaldo, Lúcio Cartaxo Pontes, Maria Araci de Andrade Cruz, Rossilene Gonçalves, Heitor de Sá Penna, Maria Lucia Fernandes Penna, Gerson Oliveira Stefani, Mariane Martins de Araújo |
dc.subject.mesh.pt_BR.fl_str_mv |
Antibodies, Bacterial Antigens, Bacterial Antitubercular Agents Clofazimine Dapsone Drug Administration Schedule Enzyme-Linked Immunosorbent Assay Immunoglobulin M Leprosy, Multibacillary Mycobacterium leprae Randomized Controlled Trials as Topic Rifampin Treatment Outcome |
topic |
Antibodies, Bacterial Antigens, Bacterial Antitubercular Agents Clofazimine Dapsone Drug Administration Schedule Enzyme-Linked Immunosorbent Assay Immunoglobulin M Leprosy, Multibacillary Mycobacterium leprae Randomized Controlled Trials as Topic Rifampin Treatment Outcome LID-1 ND-O-LID Leprosy Multidrug therapy Phenollic glycolipid-I antigen Serology Mycobacterium leprae Hanseníase Sorologia Antígenos de Bactérias Ensaios Clínicos Controlados Aleatórios como Assunto Resultado do Tratamento Esquema de Medicação |
dc.subject.en.pt_BR.fl_str_mv |
LID-1 ND-O-LID Leprosy Multidrug therapy Phenollic glycolipid-I antigen Serology |
dc.subject.decs.pt_BR.fl_str_mv |
Mycobacterium leprae Hanseníase Sorologia Antígenos de Bactérias Ensaios Clínicos Controlados Aleatórios como Assunto Resultado do Tratamento Esquema de Medicação |
description |
Colaboração de dados de Carlos Sarina (Fiocruz Brasília). |
publishDate |
2018 |
dc.date.issued.fl_str_mv |
2018 |
dc.date.accessioned.fl_str_mv |
2020-05-08T19:10:51Z |
dc.date.available.fl_str_mv |
2020-05-08T19:10:51Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
HUNGRIA, Emerith M. et al. Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT. Frontiers in Immunology, [Lausanne], v. 9, n. 915, p. 1-15, May 2018. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/41173 |
dc.identifier.issn.pt_BR.fl_str_mv |
1664-3224 |
dc.identifier.doi.none.fl_str_mv |
10.3389/fimmu.2018.00915 |
identifier_str_mv |
HUNGRIA, Emerith M. et al. Mycobacterium leprae-specific antibodies in multibacillary Leprosy patients decrease during and after treatment with either the regular 12 doses multidrug therapy (MDT) or the uniform 6 doses MDT. Frontiers in Immunology, [Lausanne], v. 9, n. 915, p. 1-15, May 2018. 1664-3224 10.3389/fimmu.2018.00915 |
url |
https://www.arca.fiocruz.br/handle/icict/41173 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/41173/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/41173/2/ve_Emerith_Hungria_etal.pdf https://www.arca.fiocruz.br/bitstream/icict/41173/3/ve_Emerith_Hungria_etal_Suppl.pdf https://www.arca.fiocruz.br/bitstream/icict/41173/4/ve_Emerith_Hungria_etal.pdf.txt https://www.arca.fiocruz.br/bitstream/icict/41173/5/ve_Emerith_Hungria_etal_Suppl.pdf.txt |
bitstream.checksum.fl_str_mv |
d3e717dbb24bfc607ede047f44d29a0e 6f48fcb00d676b0e7c8abe65ad0835d7 5c91d51444abe5add995680271ebb53b 79ab1d791b9076dd1818f5959d432111 0d9a63f57a606295e96698a93983f134 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813009041677352960 |